Dietary changes to support immune health in children with peanut and nut allergies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the relationship between gut permeability and threshold levels for peanut and nut allergies in children. It aims to determine how an immune-supportive diet may restore gut permeability and alleviate allergic symptoms. The study will include children aged 3 to 17 who have a confirmed allergy to peanuts or nuts, and will assess their reactions to these allergens through controlled challenges. The research seeks to provide insights into the underlying mechanisms of allergic reactions and the potential role of diet in managing these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children of 3 to 17 years of age with a positive open or double-blind placebo-controlled peanut or nut challenge \< 12 months to inclusion OR an obvious and objective IgE-mediated allergic reaction following the consumption of isolated peanut or nut within 1 hours, confirmed by sensitisation to peanut or nut \< 24 months to inclusion;
* Children who are potty trained or house trained;
* Presence of IgE to peanut ≥0.35 kilo units per liter (kU/l) or skin prick test \> 3 mm to peanut or nut, \< 12 months prior to challenge.

Exclusion Criteria:

* Only mild symptoms in the oral cavity to peanut or nut due to pollen food syndrome;
* A negative peanut or nut challenge;
* Children who are not potty trained (house trained);
* Gastro-intestinal diseases (e.g. Morbus Crohn, coeliac disease, Colitis Ulcerosa), lactose intolerance
* severe cow's milk allergy -because of possible traces of cow's milk in lactose in the SAT), syndromes, infectious/immunology diseases other than atopy, or diabetes;
* Laxative treatment, such as lactulose;
* Not able to read or write Dutch.

Where it's running

• Olvg
  Amsterdam, Netherlands Recruiting

Study contacts

• Study coordinator: Berber Vlieg-Boerstra
• Email: b.vlieg-boerstra@olvg.nl
• Phone: +31620965612

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remibrutinib for IgE-mediated peanut, milk, and egg allergy

  This study tests whether remibrutinib can help people with peanut, milk, or egg allergies by comparing it to placebo over 52 weeks.

  Recruiting at 22 sites Phase 3 Novartis · Birmingham, Alabama and 21 other locations · NCT07768371

• UKK-0018 immunotherapy for peanut allergy

  This trial will test whether injections of UKK-0018 can retrain the immune system to reduce allergic reactions in adults with peanut allergy.

  Recruiting at 5 sites Phase 1/2 Ukko Inc · Camperdown, New South Wales and 5 other locations · NCT07349212

• ENP-501 for people with and without peanut allergy

  This trial will test whether ENP-501 is safe and how it affects people aged 14–50 who either have a confirmed peanut allergy or regularly eat peanuts without problems.

  Recruiting Phase 1/2 N-Fold, LLC · Aurora, Colorado · NCT07117669

• Tezepelumab with Peanut OIT for Peanut Allergy

  This study tests whether adding tezepelumab to peanut oral immunotherapy can help people with peanut allergy build lasting tolerance.

  Recruiting at 6 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Little Rock, Arkansas and 9 other locations · NCT07015996

• Investigating new methods for oral immunotherapy in food allergies

  This study is testing new ways to use oral immunotherapy to help people with food allergies, like those to peanuts and milk, feel safer and have fewer allergic reactions during treatment.

  Recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT06256146

• Oral Microbiota Transplantation for Peanut Allergy Treatment

  This study is testing if a new treatment using gut bacteria can help teenagers with peanut allergies tolerate peanuts better.

  Recruiting Phase 2 Boston Children's Hospital · Boston, Massachusetts · NCT05695261

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.